XML 27 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details Textual) (USD $)
0 Months Ended 12 Months Ended
Jan. 06, 2014
Dec. 31, 2014
Dec. 31, 2013
Allocated Share-based Compensation Expense   $ 1,892,835us-gaap_AllocatedShareBasedCompensationExpense $ 979,151us-gaap_AllocatedShareBasedCompensationExpense
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   337,689us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross 354,027us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized   1,600,000us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition   2 years 5 months 8 days  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 5.45us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue  
Cash and Cash Equivalents, Fair Value Disclosure   0us-gaap_CashAndCashEquivalentsFairValueDisclosure 1,933,480us-gaap_CashAndCashEquivalentsFairValueDisclosure
Performance Shares [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares 366,126us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
/ us-gaap_AwardTypeAxis
= us-gaap_PerformanceSharesMember
149,498us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
/ us-gaap_AwardTypeAxis
= us-gaap_PerformanceSharesMember
 
Allocated Share-based Compensation Expense $ 836,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_AwardTypeAxis
= us-gaap_PerformanceSharesMember
$ 166,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_AwardTypeAxis
= us-gaap_PerformanceSharesMember
$ 422,000us-gaap_AllocatedShareBasedCompensationExpense
/ us-gaap_AwardTypeAxis
= us-gaap_PerformanceSharesMember
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award     the Company modified 907,336 existing time-vested and performance stock options by lowering the exercise price to $2.81. Additionally, the Company modified the vesting terms for its unvested performance stock options and unvested restricted stock to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015.
Restricted Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     12,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
/ us-gaap_AwardTypeAxis
= us-gaap_RestrictedStockMember
Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period   0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
/ us-gaap_AwardTypeAxis
= us-gaap_RestrictedStockUnitsRSUMember
15,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
/ us-gaap_AwardTypeAxis
= us-gaap_RestrictedStockUnitsRSUMember